BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19451748)

  • 1. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis.
    Kocsis AK; Szabolcs A; Hofner P; Takács T; Farkas G; Boda K; Mándi Y
    Pancreatology; 2009; 9(4):383-91. PubMed ID: 19451748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis.
    Lindström O; Tukiainen E; Kylänpää L; Mentula P; Rouhiainen A; Puolakkainen P; Rauvala H; Repo H
    Pancreas; 2009 Nov; 38(8):e215-20. PubMed ID: 19786934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
    Clin Biochem; 2011 Jun; 44(8-9):601-4. PubMed ID: 21211520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
    Pullerits R; Bokarewa M; Dahlberg L; Tarkowski A
    Arthritis Res Ther; 2005; 7(4):R817-24. PubMed ID: 15987483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.
    Jabaudon M; Futier E; Roszyk L; Chalus E; Guerin R; Petit A; Mrozek S; Perbet S; Cayot-Constantin S; Chartier C; Sapin V; Bazin JE; Constantin JM
    Crit Care Med; 2011 Mar; 39(3):480-8. PubMed ID: 21220996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis.
    Yasuda T; Ueda T; Takeyama Y; Shinzeki M; Sawa H; Nakajima T; Ajiki T; Fujino Y; Suzuki Y; Kuroda Y
    Pancreas; 2006 Nov; 33(4):359-63. PubMed ID: 17079940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation.
    Hatada T; Wada H; Nobori T; Okabayashi K; Maruyama K; Abe Y; Uemoto S; Yamada S; Maruyama I
    Thromb Haemost; 2005 Nov; 94(5):975-9. PubMed ID: 16363239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population.
    Fukami A; Adachi H; Yamagishi S; Matsui T; Ueda S; Nakamura K; Enomoto M; Otsuka M; Kumagae S; Nanjo Y; Kumagai E; Esaki E; Murayama K; Hirai Y; Imaizumi T
    Metabolism; 2009 Dec; 58(12):1688-93. PubMed ID: 19616266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study.
    Gaïni S; Pedersen SS; Koldkjaer OG; Pedersen C; Møller HJ
    Crit Care; 2007; 11(2):R32. PubMed ID: 17346334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. sRAGE is elevated in septic patients and associated with patients outcome.
    Bopp C; Hofer S; Weitz J; Bierhaus A; Nawroth PP; Martin E; Büchler MW; Weigand MA
    J Surg Res; 2008 Jun; 147(1):79-83. PubMed ID: 17981300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.
    Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J
    Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin B-immobilized fiber hemoperfusion in septic shock patients.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
    J Crit Care; 2011 Dec; 26(6):546-9. PubMed ID: 21273029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease.
    Hoshina T; Kusuhara K; Ikeda K; Mizuno Y; Saito M; Hara T
    Scand J Rheumatol; 2008; 37(6):445-9. PubMed ID: 18720262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
    Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
    Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus.
    Ma CY; Ma JL; Jiao YL; Li JF; Wang LC; Yang QR; You L; Cui B; Chen ZJ; Zhao YR
    Scand J Immunol; 2012 Jun; 75(6):614-22. PubMed ID: 22324318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
    Basta G; Del Turco S; Navarra T; Lee WM;
    Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
    Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
    Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional role of soluble receptor for advanced glycation end products in stroke.
    Tang SC; Wang YC; Li YI; Lin HC; Manzanero S; Hsieh YH; Phipps S; Hu CJ; Chiou HY; Huang YS; Yang WS; Mattson MP; Arumugam TV; Jeng JS
    Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):585-94. PubMed ID: 23288172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis.
    Angus DC; Yang L; Kong L; Kellum JA; Delude RL; Tracey KJ; Weissfeld L;
    Crit Care Med; 2007 Apr; 35(4):1061-7. PubMed ID: 17334246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.